PUBLISHER: Allied Market Research | PRODUCT CODE: 1414723
PUBLISHER: Allied Market Research | PRODUCT CODE: 1414723
According to a new report published by Allied Market Research, titled, "Multiplex Assay Market," The multiplex assay market was valued at $3.6 billion in 2022, and is estimated to reach $7.7 billion by 2032, growing at a CAGR of 7.8% from 2023 to 2032. A multiplex assay is a laboratory technique that allows researchers to simultaneously measure multiple analytes (such as proteins, nucleic acids, or other molecules) in a single biological sample. This method is valuable in various fields of science and medicine, including genomics, proteomics, immunology, and clinical diagnostics, as it enables the efficient and cost-effective assessment of multiple parameters in a single experiment.
However, high capital investments and dearth of skilled labors are the major factors that are expected to restrict the growth of the multiplex assay market. The high procurement and operational costs along with cumbersome and complex nature of multiplex assay instruments remain a key hurdle in the multiplex assay market. Moreover, increase in validation of biomarkers in molecular and protein diagnostics, along with rise in need of high-throughput and automated systems are anticipated to create lucrative opportunities for the expansion of the global market in the future. In addition, increase in funding for clinical research and drug discovery are expected to further propel the multiplex market growth.
The multiplex assay market is segmented on the basis of type, product, application, end user, and region. On the basis of type, the market is divided into protein based multiplex assay, nucleic acid-based multiplex assay, and cell-based multiplex assays. On the basis of product, the market is classified into reagents & consumables, instruments & accessories, and software & services. On the basis of application, the multiplex assay market is segregated into clinical diagnostics, research and development, and companion diagnostics.
On the basis of end user, the market is segregated into hospitals, clinical laboratories, research institutes, and pharmaceuticals & biotechnology companies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The major players profiled in the report are Abcam plc, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., DiaSorin S.p.A. (Luminex Corporation), Illumina Inc., Meso Scale Diagnostics LLC, QIAGEN N.V., Randox Laboratories Ltd., Seegene Inc., Thermo Fisher Scientific Inc. These major players have adopted acquisition, agreement, expansion, partnership, product launch, product approval as key developmental strategy to improve the product portfolio of the multiplex assay market.
Additional benefits you will get with this purchase are:
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)